Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 4, 2008, Pages 180-189

  Sanganalmath, Santosh K ^a,b   Barta, Judit ^a,b   Takeda, Nobuakira ^c   Kumamoto, Hideo ^a,b,d   Dhalla, Naranjan S ^a,b  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Jikei University Katsushika Medical Center   (Japan)

^d Mitsubishi Pharma Europe Ltd   (United Kingdom)

Author keywords

Arrhythmias; Cardiac function; Cilostazol; Heart failure; Sarpogrelate

Indexed keywords

CILOSTAZOL; SARPOGRELATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FATALITY; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ARRHYTHMIAS, CARDIAC; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HEMODYNAMICS; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SUCCINATES; TETRAZOLES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 42149139071     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-005     Document Type: Conference Paper

References (35)

1. Barta, J., Sanganalmath, S.K., Sethi, R., Kumamoto, H., Takeda, N., Edes, I., and Dhalla, N.S. 2006. Antithrombotic agents sarpogrelate and cilostazol differentially affect ventricular arrythmias and survival in rats. Exp. Clin. Cardiol. 11: 246. [Abstract.]
2. Brasil, D., Temsah, R.M., Kumar, K., Kumamoto, H., Takeda, N., and Dhalla, N.S. 2002. Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. J. Cardiovasc. Pharmacol. Ther. 7: 53-59. doi:10.1177/107424840200700i108. PMID:12000979.
3. Brune, S., Schmidt, T., Tebbe, U., and Kreuzer, H. 1990. Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure. Cardiovasc. Drugs Ther. 4: 85-87. doi:10.1007/BF00053434. PMID:2285654.
4. Cohn, J.N., Goldstein, S.O., Greenberg, B.H., Lorell, B.H., Bourge, R.C., Jaski, B.E., et al. 1998. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med. 339: 1810-1816. doi:10.1056/ NEJM199812173392503. PMID:9854116.
5. Cone, J., Wang, S., Tandon, N., Fong, M., Sun, B., Sakurai, K., et al. 1999. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J. Cardiovasc. Pharmacol. 34: 497-504. doi:10.1097/00005344-199910000-00004. PMID:10511123.
6. Dhalla, N.S., Dent, M.R., Tappia, P.S., Sethi, R., Barta, J., and Goyal, R.K. 2006. Subcellular remodeling as a viable target for the treatment of congestive heart failure. J. Cardiovasc. Pharmacol. Ther. 11: 31-45. doi:10.1177/107424840601100103. PMID:16703218.
7. Dixon, I.M., Lee, S.L., and Dhalla, N.S. 1990. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ. Res. 66: 782-788. PMID:2155068.
8. Doggrell, S.A. 2004. Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin. Investig. Drugs, 13: 865-874. doi:10.1517/13543784.13.7.865. PMID:15212624.
9. Fujita, M., Mizuno, K., Ho, M., Tsukahara, R., Miyamoto, A., Miki, O., et al. 2003. Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart J. 145: E16. doi:10.1067/mhj.2003.176. PMID:12660685.
10. Horibe, E., Nishigaki, K., Minatoguchi, S., and Fujiwara, H. 2004. Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease. Circ. J. 68: 68-72. doi:10.1253/circj.68.68. PMID: 14695468.
11. Igarashi, M., Okuda, T., Oh-i, T., and Koga, M. 2000. Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. J. Dermatol. 27: 643-650. PMID:11092268.
12. Ikeda, K., Tojo, K., Tokudome, G., Hosoya, T., Harada, M., and Nakao, K. 2000. The effects of sarpogrelate on cardiomyocyte hypertrophy. Life Sci. 67: 2991-2996. doi:10.1016/S0024-3205(00)00879-1. PMID:11133011.
13. Jugdutt, B.I., Joljart, M.J., and Khan, M.I. 1996. Rate of collagen deposition during healing and ventricular remodeling after myocardial infarction in rat and dog models. Circulation, 94: 94-101. PMID:8964124.
14. Kasho, M., Sakai, M., Sasahara, T., Anami, Y., Matsumura, T., Takemura, T., et al. 1998. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int. 54: 1083-1092. doi:10.1046/j.1523-1755.1998. 00114.x. PMID: 9767524.
15. Kimura, Y., Tani, T., Kanbe, T., and Watanabe, K. 1985. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung, 35: 1144-1149. PMID:4074426.
16. Litwin, S.E., Katz, S.E., Morgan, J.P., and Douglas, P.S. 1994. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation, 89: 345-354. PMID:8281668.
17. Mulvagh, S., Quinones, M.A., Kleiman, N.S., Cheirif, J., and Zoghbi, W.A. 1992. Estimation of left ventricular end-diastolic pressure from Doppler transmitral flow velocity in cardiac patients independent of systolic performance. J. Am. Coll. Cardiol. 20: 112-119. PMID:1607511.
18. Naccarelli, G.V., and Goldstein, R.A. 1989. Electrophysiology of phosphodiesterase inhibitors. Am. J. Cardiol. 63: A35-A40. doi:10.1016/0002-9149(89)90391-3. PMID:2909995.
19. Nagatomo, T., Rashid, M., Abul Muntasir, H., and Komiyama, T. 2004. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol. Ther. 104: 59-81. doi:10.1016/j.pharmthera.2004.08.005. PMID:15500909.
20. Packer, M., Carver, J.R., Rodeheffer, R.J., Ivanhoe, R.J., DiBianco, R., Zeldis, S.M., et al. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325: 1468-1475. PMID:1944425.
21. Saini, H.K., Shao, Q., Musat, S., Takeda, N., Tappia, P.S., and Dhalla, N.S. 2005. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br. J. Pharmacol. 144: 202-211. doi:10.1038/sj.bjp.0705867. PMID:15665860.
22. Sanada, S., Kitakaze, M., Papst, P.J., Asanuma, H., Node, K., Takashima, S., et al. 2001. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation, 104: 705-710. doi:10.1161/hc3201.092216. PMID: 11489779.
23. 2+-dynamics in ischemic heart failure. J. Am. Coll. Cardiol. 49: 87A. [Abstract.]
24. Satomura, K., Takase, B., Hamabe, A., Ashida, K., Hosaka, H., Ohsuzu, F., et al. 2002. Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease. Clin. Cardiol. 25: 28-32. doi:10.1002/clc.4950250108. PMID:11808836.
25. Schiller, N.B., Shah, P.M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., et al. 1989. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 2: 358-367. PMID:2698218.
26. 2+-transport and gene expression in congestive heart failure are modified by imidapril treatment. Am. J. Physiol. Heart Circ. Physiol. 288: H1674-H1682. doi:10.1152/ajpheart.00945.2004. PMID: 15576437.
27. Sharma, S.K., Del Rizzo, D.F., Zahradka, P., Bhangu, S.K., Werner, J.P., Kumamoto, H., et al. 2001. Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann. Thorac. Surg. 71: 1856-1864. doi:10.1016/S0003- 4975(01)02599-1. PMID:11426759.
28. Shimizu, Y., Minatoguchi, S., Hashimoto, K., Uno, Y., Arai, M., Wang, N., et al. 2002. The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J. Am. Coll. Cardiol. 40: 1347-1355. doi:10.1016/S0735-1097(02)02158-7. PMID:12383585.
29. Sorkin, E.M., and Markham, A. 1999. Cilostazol. Drugs Aging, 14: 63-71. doi:10.2165/00002512-199914010-00005. PMID:10069409.
30. Takano, S., Hoshino, Y., Li, L., Matsuoka, I., Ono, T., and Kimura, J. 2004. Dual roles of 5-hydroxytryptamine in ischemia-reperfusion injury in isolated rat hearts. J. Cardiovasc. Pharmacol. Ther. 9: 43-50. doi:10.1177/107424840400900i107. PMID:15094968.
31. Temsah, R.M., Kumamoto, H., Takeda, N., and Dhalla, N.S. 2001. Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. Can. J. Physiol. Pharmacol. 79: 761-767. doi:10.1139/cjpp-79-9-761. PMID: 11599776.
32. Thompson, P.D., Zimet, R., Forbes, W.P., and Zhang, P. 2002. Meta-analysis of results from eight randomized placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am. J. Cardiol. 90: 1314-1319. doi:10.1016/S0002-9149(02)02869-2. PMID:12480040.
33. Tsuchikane, E., Fukuhara, A., Kobayashi, T., Kirino, M., Yamasaki, K., Kobayashi, T., et al. 1999. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation, 100: 21-26. PMID:10393676.
34. Uchiyama, S., Ozaki, Y., Satoh, K., Kondo, K., and Nisimaru, K. 2007. Effect of sarpogrelate, a 5-HT (2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cerebrovasc. Dis. 24: 264-270. doi:10.1159/000105135. PMID:17622759.
35. Wood, M.A., and Hess, M.L. 1989. Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. Am. J. Med. Sci. 297: 105-113. doi:10.1097/00000441-198902000-00006. PMID:2521982.